Table 2.

Benchmarks.

Outcome	Target	Actual
Safety	No clinical deterioration or increase in suicidal ideation possibly related to study participation	0 participants reported worsening due to study participation
Feasibility (% eligible provided consent)	50% of eligible participants provide consent	43/45, 95%
Adherence to WSAPa exercises	50% complete sessions 3 times per week during the treatment phase	Week 1: 29/31, 93%; week 2: 29/31, 71%; week 3: 24/31, 77%; and week 4: 21/31, 68%
Adherence to study assessments	75% complete assessments	Baseline: 37/43, 86% and posttreatment: 27/31, 87%
Credibility	At least moderate credibility (5 on a scale of 1 to 9 for the CEQb item “How logical?”)	Mean 6.19, SD 2.15
Expectancy	At least moderate expectancy (>50% out of 100% on the CEQ item “How much improvement?”)	Mean 45.56%, SD 24.2%
Satisfaction and acceptability	Average rating of “slightly agree” (5 on a scale of 1 to 7) on the exit questionnaire	Helpfulness: mean 5.19, SD 1.44; relevance: mean 4.78, SD 1.63; easy to use: mean 6.15, SD 1.23; satisfaction: mean 5.78, SD 1.50; and recommendation: mean 5.46, SD 1.63
Interpretation bias manipulation check	75% in healthy range (≥70% accuracy) on WSAP (note that 1/31, 3% were already in the healthy range at baseline)	Posttreatment: 23/31, 74%
Symptom reduction	50% in the “none to minimal” range on GAD-7c; effect size Cohen d >0.2	Posttreatment: 9/31, 29%; Cohen d=0.41

^aWSAP: Word Sentence Association Paradigm.

^bCEQ: Credibility and Expectancy Questionnaire.

^cGAD-7: Generalized Anxiety Disorder-7.